Intravesical gemcitabine for non‐muscle invasive bladder cancer

BACKGROUND: It remains unclear whether people with non‐muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. This is an update of a Cochrane Review first publishe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Han, Mi Ah, Maisch, Philipp, Jung, Jae Hung, Hwang, Jun Eul, Narayan, Vikram, Cleves, Anne, Hwang, Eu Chang, Dahm, Philipp
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2021
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8202966/
https://ncbi.nlm.nih.gov/pubmed/34125951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD009294.pub3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars